Introducing Felix™ in China: Hassan Bakos Visits Leading ART Clinic Ahead of ISRG 2025

Ahead of his keynote presentation at the 2025 Annual Conference of the International Society for Reproductive Genetics…

Read More

A/Prof Hassan Bakos is delivering a plenary keynote at the 2025 International Society for Reproductive Genetics Conference in China.

A/Prof Hassan Bakos has been invited to deliver a keynote plenary at the 2025 International Society for Reproductive…

Read More

Felix™ System in new markets

Looking Back: A Year of Growth and Progress at Memphasys

From launching our Felix™ System in new markets to expanding our partnerships globally, we’ve been laser-focused on our…

Read More

Advancements in Fertility Technology: Memphasys’ Cutting-Edge Solutions

Advancements in Fertility Technology: Memphasys’ Cutting-Edge Solutions

As technologies such as cryopreservation continue to progress, we remain at the forefront, offering solutions designed…

Read More

Male Infertility in India

The Growing Challenge of Male Infertility in India: New Solutions on the Horizon

Male infertility has emerged as a significant health issue in India, accounting for nearly 40-50% of all infertility…

Read More

Over $1M in Funding Secured to Accelerate Innovations in Reproductive Biotechnology

Over $1M in Funding Secured to Accelerate Innovations in Reproductive Biotechnology

We are excited to announce significant financial developments that promise to propel our innovative projects forward.…

Read More

Memphasys Limited (ASX: MEM) is an Australian-based reproductive biotechnology company commercialising the Felix™ System, a patented bio separation technology that isolates the most viable sperm cells for human assisted reproduction.

For investor and media enquiries:
David Tasker, Chapter One Advisors
E: dtasker@chapteroneadvisors.com.au
M: +61 433 112 936

Find

Level 1, 34-36 Richmond Road,
Homebush West, NSW 2140
Australia

Call

Privacy Preference Center